Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy)
of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral
linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial
skin or skin structure infection.
Phase:
Phase 3
Details
Lead Sponsor:
Durata Therapeutics Inc., an affiliate of Allergan plc